Tiocarlide

Tiocarlide
Clinical data
ATC code	J04AD02 (WHO) ;
Identifiers
	IUPAC name 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea;
CAS Number	910-86-1 ;
PubChem CID	3001386;
ChemSpider	2272774 ;
UNII	43M23X81Y2;
ChEMBL	ChEMBL214920 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H32N2O2S
Molar mass	400.578 g/mol
3D model (JSmol)	Interactive image;
	SMILES S=C(Nc1ccc(OCCC(C)C)cc1)Nc2ccc(OCCC(C)C)cc2;
	InChI InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28) ; Key:BWBONKHPVHMQHE-UHFFFAOYSA-N ;
(what is this?) (verify)

Thiocarlide (or tiocarlide or isoxyl) is a thiourea drug used in the treatment of tuberculosis, inhibiting synthesis of oleic acid and tuberculostearic acid.^[1]

Thiocarlide has considerable antimycobacterial activity in vitro and is effective against multi-drug resistant strains of Mycobacterium tuberculosis.^[2] Isoxyl inhibits M. bovis with six hours of exposure, which is similar to isoniazid and ethionamide, two other prominent anti-TB drugs. Unlike these two drugs, however, isoxyl also partially inhibits the synthesis of fatty acids.

Thiocarlide was developed by a Belgian company, Continental Pharma S.A. Belgo-Canadienne in Brussels, Belgium. The head researcher was Professor N. P. Buu-Hoi, head of Continental Pharma's Research Division.

References

↑ Phetsuksiri B, Jackson M, Scherman H; et al. (December 2003). "Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis". J. Biol. Chem. 278 (52): 53123–30. doi:10.1074/jbc.M311209200. PMID 14559907.
↑ Phetsuksiri B, Baulard AR, Cooper AM; et al. (May 1999). "Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis". Antimicrob. Agents Chemother. 43 (5): 1042–51. PMC 89109. PMID 10223912.

Template:Antiinfective-drug-stub

[1] Phetsuksiri B, Jackson M, Scherman H; et al. (December 2003). "Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis". J. Biol. Chem. 278 (52): 53123–30. doi:10.1074/jbc.M311209200. PMID 14559907.

[2] Phetsuksiri B, Baulard AR, Cooper AM; et al. (May 1999). "Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis". Antimicrob. Agents Chemother. 43 (5): 1042–51. PMC 89109. PMID 10223912.

[1]

[2]

v t e Antimycobacterials (J04)
Tuberculosis/ tuberculosis treatment	Aminosalicylic acid (Calcium aminosalicylate, Sodium aminosalicylate) Antibiotics (Amikacin, Capreomycin, Cycloserine, Kanamycin, Rifabutin, Rifampicin, Rifamycin, Rifapentin, Streptomycin) hydrazides (Isoniazid) thiocarbamides (Ethionamide, Protionamide, Tiocarlide) Others (Ethambutol, Morinamide, Pyrazinamide, Terizidone)
Leprosy	Aldesulfone sodium • Clofazimine • Dapsone • Rifampicin

Clinical data


ATC code	J04AD02 (WHO)
Identifiers
IUPAC name 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
CAS Number	910-86-1^N
PubChem CID	3001386
ChemSpider	2272774^Y
UNII	43M23X81Y2
ChEMBL	ChEMBL214920^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₃₂N₂O₂S
Molar mass	400.578 g/mol
3D model (JSmol)	Interactive image
SMILES S=C(Nc1ccc(OCCC(C)C)cc1)Nc2ccc(OCCC(C)C)cc2
InChI InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)^Y Key:BWBONKHPVHMQHE-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Tiocarlide

References

Navigation menu

Search